Predicting vaccine effectiveness in Mpox

1

26

2 Authors: Matthew T. Berry¹, Shanchita R. Khan¹, Timothy E. Schlub^{1,2}, Adriana 3 Notaras¹, Mohana Kunasekaran¹, Andrew E. Grulich¹, C Raina MacIntyre^{1,3}, 4 Miles P. Davenport¹, David S. Khoury¹ 5 6 Affiliations: 7 1. Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia. 8 9 2. Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia. 10 3. College of Public Service & Community Solutions, and College of Health 11 Solutions, Arizona State University, Tempe, United States. 12 13 14 15 # corresponding authors: **David Khoury** 16 17 Kirby Institute, UNSW Sydney Kensington, NSW 2052 18 19 dkhoury@kirby.unsw.edu.au 20 21 Miles Davenport 22 Kirby Institute, UNSW Sydney 23 Kensington, NSW 2052 m.davenport@unsw.edu.au 24 25

Abstract:

The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was widely deployed to prevent Mpox during the 2022 global outbreak. This vaccine was initially approved for Mpox based on its reported immunogenicity and effectiveness in animal models, rather than evidence of clinical efficacy. However no validated correlate of protection after vaccination has been identified. Here we performed a systematic search and meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is predictive of vaccine effectiveness against Mpox. We observe a significant correlation between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the existing assumption that antibody levels may be a correlate of protection. Combining this data with analysis of antibody kinetics after vaccination, we predict the durability of protection after vaccination and the impact of dose spacing. Although further work is required to validate this correlate, this study provides the first evidence-based approach for using antibody measurements to predict the effectiveness of Mpox vaccination.

42 Mpox virus (formerly Monkeypox) is a zoonotic virus endemic in West Africa, with significant outbreaks in 1980-1986 and in 1997-1998¹, resulting in over 20,000 total recorded 43 44 cases. Prior to 2017, these outbreaks were typically small and initiated by zoonotic transmission followed by self-terminating human-to-human chains of transmission². 45 However, since 2017, there has been a resurgence of Mpox in Nigeria, Democratic Republic 46 of the Congo (DRC) and other parts of Africa, attributed to waning immunity from smallpox 47 48 vaccines and accumulation of cohorts that have never been vaccinated against smallpox³. In 2022, a global outbreak of Mpox resulted in 91000+ confirmed cases in 115 countries and 49 50 established chains of human-human transmission leading to a renewed focus on vaccination as a preventative measure for Mpox⁴. 51 Although there is no Mpox-specific vaccine, first generation smallpox vaccination was 52 observed to protect individuals against Mpox infection during the 1980-1986 Mpox outbreak 53 in the DRC (then Zaire)⁵⁻⁸, with an estimated vaccine effectiveness of approximately 85%⁵, 54 and this has also been observed in similar subsequent studies⁹⁻¹¹. However, the live-55 replicating vaccinia vaccines (first and second-generation) have significant risks of serious 56 vaccine adverse events¹², which led to the development of the third-generation Modified 57 Vaccinia Ankara live-attenuated (replication deficient) vaccine (MVA-BN). Prior to the 2022 58 59 Mpox outbreak, MVA-BN was approved by the FDA for use as a Smallpox and Mpox vaccine (two doses of 1×10^8 TCID via subcutaneous injection). Given the challenge of 60 directly assessing the efficacy of this vaccine in an RCT, regulatory approval was based on 61 demonstrated non-inferior immunogenicity profile and improved safety compared to the 62 second-generation ACAM2000 vaccine¹³. In particular, comparing vaccinia neutralizing 63 antibody titers induced by vaccination of MVA-BN and ACAM2000, it was deemed 64 "reasonable to expect that this regimen of the vaccine is effective in smallpox vaccinia-naïve 65 as well as in smallpox vaccine experienced individuals"¹³. This was supported by studies in 66 nonhuman primates implicating antibodies directly in mediating protection against lethal 67 Mpox challenge¹⁴. 68 69 Analysis of case data during the 2022 global outbreak indicates that the MVA-BN vaccine is effective for prevention of Mpox¹⁵⁻²⁰, and affirms the decisions to use these vaccines during 70 the outbreaks. However, important questions remain to be addressed. Firstly, how does 71 MVA-BN effectiveness compare with the protection conferred by the live replicating 72 smallpox vaccines, and how many doses are required? Further, is the protection from MVA-73 74 BN vaccination expected to be durable, and will further booster doses be required to confer 75 durable protection against Mpox and protect individuals in potential future outbreaks?

Here we address these questions by aggregating the available data on the effectiveness of different vaccinia-based vaccination regimes in protection against Mpox. We compare protection from first generation smallpox vaccines with the protection conferred by one or two doses of the MVA-BN vaccine. Further, given the assumed role of antibodies, we aggregate data on vaccinia-specific ELISA endpoint titers (here after referred to as vaccinia-binding titers) after MVA-BN vaccination (which have been shown to correlate with neutralizing antibody titers to Mpox after vaccinia vaccination²¹), and study the relationship

between antibody levels and effectiveness. Finally, we analyze the kinetics of antibody decay

over time to predict the duration of protection afforded by 1, 2 or 3 doses of vaccination. This work offers a data-driven approach to support public health decision making on Mpox

vaccination and boosting campaigns.

Results

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Search results of vaccine effectiveness and immunogenicity studies Our search identified 14 studies of vaccine effectiveness against Mpox that met the inclusion criteria (fig. S1). These studies included analysis of secondary contacts (n=5), case-coverage studies (n=5), a cohort study (n=1), and case-control studies (n=3) (Table S1). Of these studies, seven reported vaccine effectiveness from first generation smallpox vaccination, three determined effectiveness after one-dose of MVA-BN only, and four studies included protection from both one and two doses of MVA-BN. One study by Payne et al.²² was excluded, because a more recent report by the same authors was identified that contained more data¹⁷. Further, another 2 studies^{5,8} were excluded as they were all performed using similar secondary contact data from the Democratic Republic of Congo during the 1980-1986 outbreaks and thus we used only the study providing the most detailed disaggregation temporally and by age⁷. Our systematic search for immunogenicity data yielded 27 clinical trials that reported on antibody responses after MVA-BN vaccination (fig. S2). A subset of 12 trials were identified that reported vaccinia-binding titers in healthy individuals²³⁻³⁵, and one further trial was published only on the clinicaltrials.gov database³⁶ (Table S2). These trials used similar methodologies to assess vaccinia-binding, allowing comparison of immunogenicity between trials. Two studies contained data on all three relevant groups (historic smallpox vaccination, 1 dose MVA-BN and 2 dose MVA-BN vaccination), and eight studies contained data for both the MVA-BN 1-dose and 2-dose groups. Vaccine effectiveness against Mpox Using the studies identified by our systematic search, we performed a meta-analysis to estimate an aggregate vaccine effectiveness (VE). In this analysis, we stratified data by vaccine type (i.e. historic first-generation, or recent 1-dose or 2-dose MVA-BN vaccination), and a hierarchical model structure was used to account for study heterogeneity (fig. 1a and Table S3). Aggregating the available data, we used a Bayesian hierarchical model to obtain best-estimates of the effectiveness for first-generation vaccines (76.5%, CI:59-87%), one dose of MVA-BN (74.2%, CI:57-84%) and two doses of MVA-BN (82.2% CI:69-89%). We observed that one dose of MVA-BN provided lower effectiveness than historic vaccination, whilst two doses provided higher effectiveness, though neither of these results were significant (OR = 1.09, CI:0.55-2.47, OR=0.75, CI: 0.37-1.73, respectively). Importantly, we

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .

had limited power to detect such a difference – and this is reflected by the large credible intervals. Despite the variation in reported VE across different studies (ranging from 35.8-86.4% for 1 dose and 66-89.5% for 2 doses), we observe a significant benefit of two dose vaccination over one dose vaccination (OR=0.69 (CI: 0.54-0.86)) – evident because four studies compared VE after 1 and 2 doses, and all four showed a trend for higher VE after 2 doses (fig. 1b).




Figure 1: The estimated effectiveness of different Mpox vaccine regimens. (A) The estimated effectiveness of first generation (1st Gen) vaccines (n= 5), a single dose of MVA-BN (n = 6), and two doses of MVA-BN (n=4) are shown. The estimated effectiveness and 95% credible intervals (shapes and error bars) in each study along with the combined estimates for effectiveness (black circle) for different regimes are shown. Where two regimes were compared in the same study, the effectiveness of the two regimes is joined by a line. (B) The additional protection (odds ratio) provided by a two-dose regime compared to a one dose regime. The combined estimates (black) are the medians of the posterior distribution (circle) with the 95% credible intervals (error bars).

Vaccinia-binding titers in vaccinated individuals

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164165

To investigate the immunogenicity of different vaccination strategies, we aggregated data on the geometric mean vaccinia-binding titers (GMT) reported 4 weeks after 1 dose MVA-BN and 2 weeks after 2 dose MVA-BN. Our analysis aggregated data from studies that used slightly different ELISA assay protocols to estimate antibody titers (Table S2). We fit a Bayesian model with covariates for vaccine formulation and ELISA assay used, and a hierarchical structure to account for interstudy variability (see Methods, Table S4). Interestingly, we found no significant effect of the ELISA assay used to measure the GMT (fig. S3a), but the formulation of the vaccine had a significant effect on the antibody titer (freeze dried formulation provided higher titers than liquid frozen, p<0.001) (fig. S3b). Since the liquid frozen formulation was the formulation deployed in the effectiveness studies, we focus our analysis on this formulation. After accounting for all study and formulation differences, we found that the GMT induced by one dose of liquid frozen MVA-BN provides a higher antibody level than that observed in individuals who received a first-generation vaccine historically (GMT = 87.2 (CI: 66.9-115) vs 58.7 (CI: 41.4-82.2), fold difference 1.49 (CI:1.16-1.92)), and a second dose of liquid frozen MVA-BN provided a significant boost over a single dose (8.42-fold (CI: 7.79-9.10) increase, fig. 2).




Figure 2: Comparison of the reported geometric mean vaccinia-binding titers induced by vaccination with MVA-BN and historic first-generation vaccines. The GMTs from the freezedried MVA-BN formulation (light-color) are significantly higher than the liquid frozen formulation (dark-color) (1.32-fold, CI:1.20-1.48, p<0.001). Horizontal lines indicate the

combined estimate (median of the posterior distribution) for each vaccination and formulation (dashed lines are the 95% credible intervals).

Estimating a quantitative relationship between vaccinia-binding titers and vaccine

effectiveness

166

167 168 169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

Antibody titers are thought to be a surrogate of vaccine effectiveness for both smallpox and Mpox infection^{14,37}, and were used to support the regulatory approval of MVA-BN¹³. This is supported by animal studies showing an important role of antibodies in protection from Mpox¹⁴. Thus, we sought to investigate the relationship between vaccinia-binding antibody titer and effectiveness by combining the available immunogenicity data and effectiveness data. No study found in our searches contained both effectiveness data and immunogenicity data from the same cohort. Therefore, we matched the immunogenicity data to the corresponding vaccine effectiveness data by vaccine regimen. That is, 1-dose MVA-BN vaccination (n=10 immunogenicity, and n=6 effectiveness studies, respectively), 2-dose MVA-BN vaccination (n=11, and n=4) and historic first-generation smallpox vaccination (n=3, and n=5). Although we have very limited data to assess a correlation (i.e. only three vaccine groups across 14 effectiveness and 13 immunogenicity studies), fitting a logistic relationship between antibody titers in these groups and effectiveness (following the approach used in COVID-19^{38,39}) (fig. 3), we found evidence of a significant positive association between antibody titers and effectiveness (OR: 0.62 (CI 0.47-0.82) for each 10fold change in vaccinia-binding, p<0.001) (Table S5). This supports the use of vacciniabinding titers as a correlate of vaccinia-based vaccine effectiveness. Further, this model provides a quantitative method to predict vaccine effectiveness (along with credible intervals) associated with different antibody titers and waning immunity.

perpetuity.

It is made available under a CC-BY-NC 4.0 International license .




Figure 3: Relationship between vaccine effectiveness and the vaccinia-binding GMT. The global estimates of vaccine effectiveness and vaccinia-binding titers across different vaccination regimes are shown with colored contour lines. The contours represent the lines of equal probability of the normalized joint-posterior density (combining posterior densities from the vaccine immunogenicity and effectiveness analyses, i.e. fig. 1 and 2, respectively). The association between antibody titers and effectiveness (solid black line) is fitted using all of the underlying data (accounting for the interstudy heterogeneity using a hierarchical model structure) (Table S5). The solid black line indicates the best estimate (median of posterior), and shaded region show the 95% credible intervals of the predicted effectiveness at different GMTs.

Boosting and waning of antibody titers with MVA-BN vaccination

A major question regarding Mpox control is how to optimize vaccine distribution and dosing intervals in the context of a potential future outbreak. Estimates of both the durability of protection and of the effects of the interval between first and second dose of MVA-BN would be informative in guiding policy for future responses. The immunogenicity studies we identified included a subset of studies that reported long-term follow up of antibody titers after MVA-BN vaccination (up to 24 months), as well as the effects of different timing of a second MVA-BN dose^{24,25,27-36}. To explore the effect of dose timing on the peak and durability of antibody responses, we fitted a two-phase antibody decay model to the available vaccinia-titers over time for different vaccination regimens (fig. 4a). From this analysis we firstly noted, consistent with other vaccines⁴⁰, increased spacing between MVA-BN vaccine doses led to a higher peak antibody response (measured at 14 days post-last dose or 28 days post-initial dose, whichever is later) (fig. 4b). For example, delaying the timing of the second

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

dose from 7 days to 28 days led to a 4.2-fold (CI: 2.1-8.8) higher antibody titer. Delay from 28 days to 730 days led to a 3.2-fold (CI:2.6-3.8) higher titer. Interestingly, the peak antibody titer after a second dose of MVA-BN at 730 days was very similar to the peak titer of a third dose of MVA-BN at 730 days (after an initial 28 day-spaced two-dose regime) (GMR 1.03, CI:0.82-1.31). Regarding decay, we observed a fast initial decay and slow long-term decay of antibody titers (i.e. model comparison indicates that a two-phase decay model is superior to a single-phase decay, Table S7), and the estimated half-life of the fast-decaying and slow-decaying antibody titer was 20.7 (CI:18.2-24.0) days and 1721 (CI:971-6459) days, respectively. The estimated decay rates of the fast and slow-decaying antibodies were not different between the regimes (Table S7). However, the initial antibody titer and proportion of slow-decaying (long-lived) antibodies varied between groups (fig. 4 and S4, discussed below). Interestingly, the proportion of long-lived antibodies increased in individuals with a 730-day spacing between first and second dose, when compared with the standard two dose schedule (fig. S4 & Table S8). Thus, when we consider the predicted antibody titers one year after boosting, delaying the second dose to 730 days provides a 17.0 (CI: 13.5-21.2) fold higher titer compared to standard boosting at 28 days (fig. 4c and Table S8). Interestingly, whether vaccination at 730 days was given as a second booster, or as a third booster (after a second at 28 days), the durability of the response was similar (GMR 1 year after peak of 3 doses to 2 doses: 1.2 (CI:0.89-1.63)). Of note, we estimate that antibody titers after 2 doses of MVA-BN vaccination (with 28-day interval) remain above or equal to the peak GMT of one dose for 81 days (CI:72-93) and above historically vaccinated cohorts for 102 days (CI: 74-173). By delaying the second dose to two years, antibody titers remain above the one-dose peak for 13.2 years (CI:7.5-48.3 years). Together these results suggest that a delayed booster or third dose provides higher and more durable antibody titers.




Figure 4: Predicting the durability of protection: (A) The decay in GMT in the different immunogenicity trials as fitted using a two-phase decay model. The estimated GMT (solid lines) and 95% credible intervals (shaded) are shown over the two-year period for which immunogenicity data was measured in the one and two dose schedules. (B) The effect of delayed dosing. The GMT at the approximate peak (2 weeks after the final dose or 28 days after the first dose, whichever is later) is shown for different MVA-BN vaccination regimes. (C) The predicted GMT one-year postvaccination, accounting for the early fast-decay and the late slow-decay of antibodies (Table S8). Predicted GMTs for regimens without a datapoint later than 5 months post-vaccination are faded. (D) The predicted vaccine effectiveness over a 10-year period for the different vaccination schedules. The

246

247

248

249

250

251

252

255

256 257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

grey region highlights the prediction extrapolated beyond the available time course of immunogenicity data. The three-dose schedule involves vaccination on day 28 and 2 years after the initial dose (3rd dose delivered on day 730). **Predicting vaccine effectiveness** Using the decay kinetics of antibody titers estimated above (fig. 4a), and the logistic relationship between antibody titers and vaccine effectiveness (fig. 3), we can predict the duration of vaccine protection under different vaccine schedules (fig. 4d). Our analysis predicts vaccination with one dose of MVA-BN will have an effectiveness of 66.6% (CI:51.87-77.7) at 2 years post vaccination (note that this VE estimate is an extrapolation below the range of data in fig. 3). A two-dose regimen on a 4-week schedule is anticipated to still provide 73.2% (CI:61.9-81.4) effectiveness from Mpox infection at 2 years. Extrapolating antibody decay beyond the available time series (shaded region in fig. 4d), we also predict the level of long-term effectiveness from 1 and 2-dose MVA-BN vaccination (with 28-day spacing) after 10 years will be 61.3% (CI: 42.6-75.4) and 68.4% (CI:53.0-78.9), respectively. This is based on the conservative assumption that antibody decay continues at the same rate over 10 years (although studies of antibody decay after first generation vaccinia vaccination suggest the half-life may continue to slow to as long as 99 years³⁷). If the second vaccination is delayed to 730 days, then the predicted effectiveness at 10 years post-boost is 78.6% (CI:68.7-85.8). Together this analysis predicts long-term protection against Mpox after 1, and especially 2 doses of MVA-BN vaccination.

Discussion

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

The ongoing spread of Mpox in West and Central Africa, the 2022 global pandemic, and the associated changing epidemiology of Mpox virus highlight the importance of an improved understanding of Mpox vaccination and immunity. Novel vaccinia-based vaccines were anticipated to be as effective against Mpox as historical first-generation smallpox vaccines^{5,7}. However, determining the efficacy of novel Mpox vaccines has proved challenging due to the difficulties in performing large randomized controlled trials (RCTs). In lieu of RCTs, a correlate of protection from immunogenicity data can be used in the vaccine development process. Neutralizing antibody titers have been proposed as a correlate due to their role in protection from a lethal Mpox challenge in animal models¹⁴. Subsequently, neutralizing antibodies and animal studies formed the basis for the approval of MVA-BN as a thirdgeneration smallpox and Mpox vaccine¹³. In this work we aggregate the available data to study the relationship between vaccine immunogenicity and vaccine protection from Mpox infection. Analysis of the vaccine effectiveness data indicates that single dose MVA-BN is non-inferior to historical vaccination with first generation smallpox vaccines (OR = 1.09, (CI:0.55-2.47)). These findings support the choice to adopt MVA-BN vaccine for control of Mpox given its comparable effectiveness to first generation vaccines, and its beneficial safety profile³². Further, our meta-analysis finds 2 dose MVA-BN vaccination to be more effective than 1 dose (OR=0.69 (CI: 0.54-0.86)). A validated surrogate marker of Mpox immunity would greatly assist in vaccine development and deployment, and in predicting the longevity of protection and necessity for boosting. Here we find a weak but significant association between antibody titers and vaccine effectiveness, albeit with very limited data. The significance of this association is predominantly influenced by the result that 2 doses of MVA-BN has both higher effectiveness and higher antibody titers than 1 dose. Caution is required before interpreting this result as a demonstration of antibody titers as a correlate of protection for vaccinia vaccines against Mpox, since we have limited data available, a small range in observed effectiveness, and large interstudy variation. Our observation, however, supports the existing results from animal models that antibodies may be a correlate of protection against Mpox¹⁴. If we assume that antibody titers are indeed a correlate, our model provides confidence limits for the long-term effectiveness given the available data. A major challenge during the 2022 global Mpox outbreak was prioritizing the use of the small pool of existing MVA-BN

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

vaccines. In particular, it was unclear whether improved overall outcomes would be achieved by, 1) maximizing the number of individuals who could receive a first dose, thus giving them some protection, or 2) focusing on maximizing the number of individuals who could receive the full two dose regimen and ensure they had a sufficient immunological response for protection. Our analysis suggests that 2-doses of the vaccine provide only a slight increase in effectiveness compared to 1-dose (82.2% vs 74.2%). Therefore, in the context of a limited number of available doses, the increase in protection provided by a second dose (to recently vaccinated individuals) is less than the protection that could be obtained by giving a single dose to as many naïve individuals as possible. Assuming a population with equal risk, 1.81times (CI:1.58-1.93) more cases could be averted by giving a single dose to twice as many individuals rather than a full 2 doses to a smaller group. Initially administering a single dose to the maximum number of people and delaying a second dose until there is increased availability of vaccine may provide additional benefits in terms of the durability of protection. For example, delaying a second dose until 2 years after the first dose is expected to provide a 3.2-fold higher peak titer and 14.1-fold higher titer at 1 year (compared to a second dose at 28 days) (fig. 4a). Even though delaying a second dose produces a longer period of lower protection before boosting, protection from a single dose of MVA-BN is predicted to remain >65% at 2 years (compared to 72% at 2 years for a 2-dose regime) (fig. 4d). Further work is required to understand the optimal spacing of booster doses to maximize both short and long-term protection. However, these data predict that administering single doses initially allows the deployment of the vaccine more rapidly to more individuals during an emergency, and by delaying the second dose there is a potential advantage to the long-term durability of protection. Our analysis includes a significant number of limitations. Firstly, the studies on vaccine effectiveness show a large amount of study heterogeneity (Table S1). For example, the estimated vaccine effectiveness after one dose of MVA-BN varies between 35.8% (CI:22.1-47.1)¹⁶ to 86.4% (CI:83.3-89.0)¹⁷. This is perhaps not surprising, given the effectiveness data was obtained from observational studies with different study designs and potential confounders. A major challenge in using non-randomized studies is appropriate matching of control groups (in case-control studies) and identification of the at-risk population (in case-coverage studies). Differences in matching cases to controls significantly affect the reported levels of protection^{15,16,19}. In addition, large case-coverage studies attribute the reduction in case

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

numbers to vaccination, but this may not control for confounders such as differences in behavior (which have been associated with a reduction in spread in Italy prior to the commencement of vaccination⁴¹). These confounders may contribute to the substantial heterogeneity in VE observed across studies (fig. 1). We can partially account for unmeasured confounding by using a hierarchical model to account for inter-study variability, but systematic biases that result from unmeasured confounding are unable to be completely excluded. Further, the route and dose of MVA-BN administered varied over time and in different regions. For example, during the 2022 outbreak, following changes in FDA recommendations in the US, 45.9% of individuals received their first dose (and 85.7% received their second dose) via an intradermal (ID) injection of 2 x 10⁷ TCID, instead of the per label recommendation of 1 x 108 TCID administered subcutaneously (SC)⁴². Our analysis of the effectiveness data could not test whether protection was impacted by the method of administration since the effectiveness studies did not disaggregate data by mode of administration (SC or ID). However, Panye et al.¹⁷, who tested for a difference in VE between individuals who received SC and those who received ID, reported no difference. Another limitation is that the VE data and immunogenicity data came from independent cohorts and studies. Thus, there is no guarantee that the populations are well matched. Specifically, there is a significant mismatch in the demographics of the vaccine effectiveness studies and the immunogenicity trials. For example, the population considered in the US study for vaccine effectiveness¹⁷ considered only men (sex assigned at birth or gender identity) aged between 18-49. On the other hand, the clinical trials of antibody responses post vaccination were all tested on populations of both men and women and featured slightly different age ranges. Further, even though the majority (85.7%) of individuals in the US received their second dose of MVA-BN via intradermal administration⁴², the majority of the available immunogenicity data was from individuals with SC administration (creating a potential mismatch in the effectiveness data and immunogenicity data). Fortunately, immunogenicity data suggests similar antibody titers between the two modes of administration²⁴. An additional difference between immunogenicity and effectiveness studies was in the time between vaccination and serum sampling and effectiveness assessment. Whereas immunogenicity was assessed at 4 or 2 weeks after first or second vaccination respectively, the time from vaccination to infection is only reported in one study (Wolff Sagy et al. 18, where 3 of 5 infections occur in week 3, and the other two infections occur in week

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

6). A mismatch also exists in comparing historic first-generation vaccination. The effectiveness data are from studies in the Democratic Republic of Congo in the 1980s to 2010s, whereas the immunogenicity data are from individuals in the United States (who in most cases were vaccinated >40 years earlier). As well as differences in the viral clades between these outbreaks^{43,44}, timing of previous vaccination in the historic vaccine effectiveness studies is not recorded and may not be well matched to the immunogenicity studies. Evidence of a very slow long-term decay of antibodies^{37,45-47} suggests that timesince-vaccination may not be critical in comparing these groups many years after vaccination. However, it was not possible to match for age of vaccination, health status, or other demographic variables and their effects on immunogenicity and protection are unknown. Previous work has shown that vaccination in childhood confers longer protection than vaccination in adulthood⁴⁸. Further investigation of the risk of breakthrough infection in historically smallpox vaccinated cohorts are required to confirm this assumption and improve our understanding of the duration of Mpox immunity from vaccinia vaccines⁴⁹. Finally, it is important to emphasize that we identified a relationship between vacciniabinding titers and vaccine protection. Although vaccinia-binding titers are correlated with in vitro neutralizing antibody titers to Mpox²¹, they are likely not an optimal measure of antibody effectiveness against Mpox. Further work is necessary to compare different measures of immunogenicity to better standardize assays to define a correlate of protection for Mpox. This study brings together the limited and heterogenous data available on immunogenicity and protection from Mpox after MVA-BN vaccination. We report non-inferiority of MVA-BN against Mpox compared to historic first-generation smallpox vaccination and define a candidate surrogate of vaccine effectiveness based on vaccina-binding titers. We then use that surrogate to predict the duration of vaccine effectiveness. We predict that, since long-term vaccinia specific titers remain high, MVA-BN vaccine effectiveness will remain >60% for up to 10 years, even after a single dose. This prediction of durable immune responses is consistent with reports of first and second generation vaccines against smallpox, where detectable immune responses and protection (particularly from severe infection) are thought to persist for over 20 years⁵⁰⁻⁵² (reviewed in Kunasekaran et al⁴⁸). Our approach allows the prediction of vaccine effectiveness based on the existing available evidence, but also indicates the urgent need for further studies of MVA-BN immunogenicity and protection.

The development of a standardized assay for Mpox antibody binding or neutralization and a serological standard for comparison are important priorities. In the absence of this, comparison between studies by normalizing antibody levels to those induced by (for example) 1 dose MVA-BN vaccination (similar to methods used in COVID-19^{38,39}) is possible but not ideal. In addition, public health plans for a potential future Mpox outbreak need to be developed, ideally informed by the best available evidence for vaccine effectiveness.

412

413

414

415

416

417

perpetuity.
It is made available under a CC-BY-NC 4.0 International license .

References

420	1	Di Giulio, D. B. & Eckburg, P. B. Human monkeypox: an emerging zoonosis. Lancet Infect Dis
421		4, 15-25 (2004). https://doi.org:10.1016/s1473-3099(03)00856-9

- Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* **13**, e0007791 (2019). https://doi.org:10.1371/journal.pntd.0007791
- Nguyen, P. Y., Ajisegiri, W. S., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Reemergence
 of Human Monkeypox and Declining Population Immunity in the Context of Urbanization,
 Nigeria, 2017-2020. *Emerg Infect Dis* 27, 1007-1014 (2021).
 https://doi.org:10.3201/eid2704.203569
- 429 4 WHO Emergency Response Team. Multi-country outbreak of mpox, External situation report#29. (2023). https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox-external-situation-report-29---20-october-2023
- Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in human populations. *Int J Epidemiol* **17**, 643-650 (1988). https://doi.org:10.1093/ije/17.3.643
- 434 6 Jezek, Z. *et al.* Four generations of probable person-to-person transmission of human monkeypox. *Am J Epidemiol* **123**, 1004-1012 (1986).

 436 https://doi.org:10.1093/oxfordjournals.aje.a114328
- Jezek, Z., Grab, B., Szczeniowski, M. V., Paluku, K. M. & Mutombo, M. Human monkeypox: secondary attack rates. *Bull World Health Organ* **66**, 465-470 (1988).
- 439 8 Jezek, Z. *et al.* Human monkeypox: a study of 2,510 contacts of 214 patients. *J Infect Dis* **154**, 440 551-555 (1986). https://doi.org:10.1093/infdis/154.4.551
- 441 9 Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci U S A* 443 **107**, 16262-16267 (2010). https://doi.org:10.1073/pnas.1005769107
- Nolen, L. D. *et al.* Introduction of Monkeypox into a Community and Household: Risk Factors and Zoonotic Reservoirs in the Democratic Republic of the Congo. *Am J Trop Med Hyg* **93**, 410-415 (2015). https://doi.org:10.4269/ajtmh.15-0168
- 447 11 Whitehouse, E. R. *et al.* Clinical and Epidemiological Findings from Enhanced Monkeypox 448 Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015. *J* 449 *Infect Dis* **223**, 1870-1878 (2021). https://doi.org:10.1093/infdis/jiab133
- 450 12 Eckart, R. E. *et al.* Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. *J Am Coll Cardiol* **44**, 201-205 (2004).
 452 https://doi.org:10.1016/j.jacc.2004.05.004
- 453 13 Summary Basis for Regulatory Action-Jynneos (US FDA,2019); 454 https://www.fda.gov/media/131802/download
- Edghill-Smith, Y. *et al.* Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. *Nat Med* **11**, 740-747 (2005). https://doi.org:10.1038/nm1261
- Dalton, A. F. *et al.* Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A
 Multijurisdictional Case-Control Study United States, August 19, 2022–March 31, 2023.
 MMWR. Morbidity and Mortality Weekly Report 72, 553-558 (2023).
 https://doi.org:10.15585/mmwr.mm7220a3
- Deputy, N. P. et al. Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States. N Engl J Med 388, 2434-2443 (2023). https://doi.org:10.1056/NEJMoa2215201
- Payne, A. B. *et al.* Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons-43 US Jurisdictions, July 31-October 1, 2022. *Mmwr-Morbidity and Mortality Weekly Report* **71**, 1560-1564 (2022).
- 467 18 Wolff Sagy, Y. *et al.* Real-world effectiveness of a single dose of mpox vaccine in males. *Nat* 468 *Med* **29**, 748-752 (2023). https://doi.org:10.1038/s41591-023-02229-3

469	19	Rosenberg, E. S. et al. Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection
470		— New York, 2022. MMWR. Morbidity and Mortality Weekly Report 72 , 559-563 (2023).
471		https://doi.org:10.15585/mmwr.mm7220a4
472	20	Bertran, M. et al. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in
473		England using the case-coverage method: an observational study. <i>Lancet Infect Dis</i> 23 , 828-
474		835 (2023). https://doi.org:10.1016/S1473-3099(23)00057-9
475	21	Zaeck, L. M. et al. Low levels of monkeypox virus-neutralizing antibodies after MVA-BN
476	21	vaccination in healthy individuals. <i>Nat Med</i> 29 , 270-278 (2023).
477		
	22	https://doi.org:10.1038/s41591-022-02090-w
478	22	Payne, A. B. et al. Incidence of Monkeypox Among Unvaccinated Persons Compared with
479		Persons Receiving ≥1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3,
480		2022. MMWR. Morbidity and Mortality Weekly Report 71 , 1278-1282 (2022).
481		https://doi.org:10.15585/mmwr.mm7140e3
482	23	Frey, S. E. et al. Human Antibody Responses Following Vaccinia Immunization Using Protein
483		Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular
484		Cytotoxicity Responses. J Infect Dis 224, 1372-1382 (2021).
485		https://doi.org:10.1093/infdis/jiab111
486	24	Frey, S. E. et al. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA)
487		formulations and subcutaneous versus intradermal routes of administration in healthy
488		vaccinia-naive subjects. <i>Vaccine</i> 33 , 5225-5234 (2015).
489		https://doi.org:10.1016/j.vaccine.2015.06.075
490	25	Frey, S. E. et al. Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using
491		different strategies for a post event scenario. <i>Vaccine</i> 31 , 3025-3033 (2013).
492		https://doi.org:10.1016/j.vaccine.2013.04.050
493	26	Greenberg, R. N. et al. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
494	20	Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine
495		(MVA-BN(R)) in 56-80-Year-Old Subjects. <i>PLoS One</i> 11 , e0157335 (2016).
496		https://doi.org:10.1371/journal.pone.0157335
490 497	27	Greenberg, R. N. <i>et al.</i> A Multicenter, Open-Label, Controlled Phase II Study to Evaluate
	27	· · · · · · · · · · · · · · · · · · ·
498		Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old
499		Subjects with Diagnosed Atopic Dermatitis. <i>PLoS One</i> 10 , e0138348 (2015).
500		https://doi.org:10.1371/journal.pone.0138348
501	28	Ilchmann, H. et al. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian
502		Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox
503		Vaccines. J Infect Dis 227 , 1203-1213 (2023). https://doi.org:10.1093/infdis/jiac455
504	29	Jackson, L. A. et al. Safety and immunogenicity of a modified vaccinia Ankara vaccine using
505		three immunization schedules and two modes of delivery: A randomized clinical non-
506		inferiority trial. Vaccine 35 , 1675-1682 (2017). https://doi.org:10.1016/j.vaccine.2017.02.032
507	30	Overton, E. T. et al. Immunogenicity and safety of three consecutive production lots of the
508		non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled
509		phase III trial. <i>PLoS One</i> 13 , e0195897 (2018). https://doi.org:10.1371/journal.pone.0195897
510	31	Overton, E. T. et al. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic
511		Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-
512		Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. Open Forum Infect Dis
513		2 , ofv040 (2015). https://doi.org:10.1093/ofid/ofv040
514	32	Pittman, P. R. <i>et al.</i> Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against
515	32	Smallpox. <i>N Engl J Med</i> 381 , 1897-1908 (2019). https://doi.org:10.1056/NEJMoa1817307
516	33	Overton, E. <i>et al.</i> A randomized phase 3 trial to assess the immunogenicity and safety of 3
517	33	consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults. <i>Vaccine</i>
518		41 , 397-406 (2023). https://doi.org:10.1016/j.vaccine.2022.10.056
310		41, 337-400 (2023). https://doi.org.10.1010/j.vaccine.2022.10.030

519	34	Zitzmann-Roth, E. M. et al. Cardiac safety of Modified Vaccinia Ankara for vaccination
520		against smallpox in a young, healthy study population. <i>PLoS One</i> 10 , e0122653 (2015).
521		https://doi.org:10.1371/journal.pone.0122653
522	35	von Krempelhuber, A. et al. A randomized, double-blind, dose-finding Phase II study to
523		evaluate immunogenicity and safety of the third generation smallpox vaccine candidate
524		IMVAMUNE. Vaccine 28, 1209-1216 (2010). https://doi.org:10.1016/j.vaccine.2009.11.030
525	36	Bavarian Nordic. A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation
526		of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects,
527		https://clinicaltrials.gov/study/NCT01668537 > (2020).
528	37	Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral
529		and vaccine antigens. N Engl J Med 357 , 1903-1915 (2007).
530		https://doi.org:10.1056/NEJMoa066092
531	38	Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection
532		from symptomatic SARS-CoV-2 infection. Nat Med 27, 1205-1211 (2021).
533		https://doi.org:10.1038/s41591-021-01377-8
534	39	Stadler, E. et al. Monoclonal antibody levels and protection from COVID-19. Nat Commun 14,
535		4545 (2023). https://doi.org:10.1038/s41467-023-40204-1
536	40	Voysey, M. et al. Single-dose administration and the influence of the timing of the booster
537		dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled
538		analysis of four randomised trials. Lancet 397, 881-891 (2021).
539		https://doi.org:10.1016/S0140-6736(21)00432-3
540	41	Vairo, F. et al. The possible effect of sociobehavioral factors and public health actions on the
541		mpox epidemic slowdown. <i>International Journal of Infectious Diseases</i> 130 , 83-85 (2023).
542		https://doi.org:10.1016/j.ijid.2023.03.005
543	42	Owens, L. E. et al. JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United
544		States, May 22, 2022–January 31, 2023. MMWR. Morbidity and Mortality Weekly Report 72,
545		342-347 (2023). https://doi.org:10.15585/mmwr.mm7213a4
546	43	Azzi, A. Unusual Monkeypox virus outbreak in 2022: Phenotypic and molecular
547		characteristics. Aspects of Molecular Medicine 1 (2023).
548		https://doi.org:10.1016/j.amolm.2023.100001
549	44	Gigante, C. M. et al. Multiple lineages of monkeypox virus detected in the United States,
550		2021–2022. Science 378 , 560-565 (2022). https://doi.org:doi:10.1126/science.add4153
551	45	Sanz-Munoz, I. et al. Possible Mpox Protection from Smallpox Vaccine-Generated Antibodies
552		among Older Adults. Emerg Infect Dis 29, 656-658 (2023).
553		https://doi.org:10.3201/eid2903.221231
554	46	Antia, A. et al. Heterogeneity and longevity of antibody memory to viruses and vaccines.
555		PLoS Biol 16, e2006601 (2018). https://doi.org:10.1371/journal.pbio.2006601
556	47	Hammarlund, E. et al. Multiple diagnostic techniques identify previously vaccinated
557		individuals with protective immunity against monkeypox. <i>Nat Med</i> 11 , 1005-1011 (2005).
558		https://doi.org:10.1038/nm1273
559	48	Kunasekaran, M. P., Chen, X., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Evidence for
560		Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence. Mil
561		Med 184, e668-e679 (2019). https://doi.org:10.1093/milmed/usz181
562	49	Jamard, S. et al. Resurgence of symptomatic Mpox among vaccinated patients: First clues
563		from a new-onset local cluster. Infect Dis Now 53, 104714 (2023).
564		https://doi.org:10.1016/j.idnow.2023.104714
565	50	Eichner, M. Analysis of historical data suggests long-lasting protective effects of smallpox
566		vaccination. Am J Epidemiol 158 , 717-723 (2003). https://doi.org:10.1093/aje/kwg225
567	51	Nishiura, H. & Eichner, M. Estimation of the Duration of Vaccine-induced Residual Protection
568		Against Severe and Fatal Smallpox Based on Secondary Vaccination Failure. <i>Infection</i> 34 ,
569		241-246 (2006). https://doi.org:10.1007/s15010-006-6603-5

570	52	Nishiura, H., Schwehm, M. & Eichner, M. Still protected against smallpox? Estimation of the
571		duration of vaccine-induced immunity against smallpox. Epidemiology 17, 576-581 (2006).
572		https://doi.org:10.1097/01.ede.0000229196.41862.c2
573	53	Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A
574		systematic review. PLoS Negl Trop Dis 16, e0010141 (2022).
575		https://doi.org:10.1371/journal.pntd.0010141
576	54	WebPlotDigitizer v. 4.6 (2022). https://automeris.io/WebPlotDigitizer
577	55	RStan: The R interface to Stan v. 2.26.23 (2023). https://mc-stan.org/
578	56	Stan Modeling Language Users Guide and Reference Manual v. 2.23 (2023). https://mc-
579		<u>stan.org</u>
580	57	Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine
581		effectiveness. Vaccine 31 , 2165-2168 (2013). https://doi.org:10.1016/j.vaccine.2013.02.053
582		

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

Methods Search strategy We aimed to aggregate the available data that reported on both vaccine protection against Mpox infection and vaccine immunogenicity in order to understand the relationship between immunogenicity and protection. For vaccine protection studies, we used a recently published systematic review⁵³ and extended this here. To obtain matching immunogenicity data, we performed a systematic search of ClinicalTrials.gov for all studies of MVA-BN immunogenicity. Search Strategy for vaccine effectiveness data Our search strategy for identifying studies of vaccine effectiveness was based upon the search strategy in the systematic review by Bunge et al.⁵³. This systematic review identified articles relating to Mpox prior to 7th September 2020. We extend this by conducting a systematic search from that date up to 10th July 2023 using the same search strategy, with the following modifications: included Mpox[tiab] to account for the recent name change, we added the search terms AND (Vaccine[tiab] OR Vaccination[tiab]), since our search results are only targeted towards vaccine effectiveness (rather than all studies reporting on Mpox). For inclusion in our analysis, a study needed to report Mpox incidence data by vaccination status along with an estimate, or the data required for estimating, the at-risk population for observational studies, or a control group in case-control studies. Search strategy for Immunogenicity Since vaccinia-binding IgG antibody titers after MVA-BN vaccination have been shown to be highly correlated with neutralizing antibodies against vaccinia and Mpox viruses²¹, and because of the limited data on in vitro neutralization of Mpox virus, we focused our search of immunogenicity data on vaccinia-binding titers. The immunogenicity data was obtained by searching through the clinicaltrials.gov database for clinical trials using the MVA-BN vaccine. We searched for intervention trials with 'MVA' as the intervention with condition, 'smallpox OR Monkeypox OR Variola'. We only considered studies that had been completed. For inclusion in our analysis, the intervention had to be MVA-BN (different types of MVA vaccines have been tested in the past but are not used for immunization against

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

Mpox). Our analysis only considers healthy individuals. Therefore, at least one arm in the trial had to include a healthy population for the trial to be included in our analysis. **Data extraction** For data on vaccine effectiveness, we extracted the case/control incidence (number of events) data reported in each study disaggregated by timepoint, age or region where possible. For immunogenicity data, we contacted the sponsor by e-mail to request access to the deidentified individual-level data presented in the published work. This request was denied (27 March 2023). Therefore, we extracted summary data (Geometric Mean Titer (GMT) and confidence intervals (CI)) from tables (where available) or figures using WebPlotDigitiser⁵⁴. Where data was extracted from an image, two individuals (MB, SRK) extracted the data independently with the geometric mean of the two extracted values used and we confirmed that discrepancies between extracted values were always less than 1%. Statistical analysis All meta-analyses and meta-regression were performed using a hierarchical Bayesian data analysis framework in RStan^{55,56} using the default HMC sampler. This included global estimates of mean effectiveness, and antibody titers after vaccination, estimates of the decay kinetics of antibody titers, and fitting the relationship between antibody titers and effectiveness. Hierarchical model structures were used to account for inter-study variability in all analyses, and unless otherwise stated all reported estimates are posterior medians, along with 95% credibility intervals (CI). To perform statistical tests of whether a parameter (or difference in parameters), g, was significantly different to zero we defined a p-value, p = $2 \times min(P(q > 0), P(q < 0))$, which was calculated from the posterior distributions of estimated parameters. Significance was defined as p<0.05. **Estimating vaccine effectiveness** In our meta-analysis of vaccine effectiveness, we implement a modified version of the Bayesian binomial approach ^{27,28} to fit the raw event data from each study. The binomial model assumes individuals in a given population, N, have an unknown probability of infection, r. Therefore, the number of infections, n, follow a binomial distribution, p(n|r) =Bin(r, N), with posterior distribution, $p(r \mid n) = \frac{p(n \mid r)p(r)}{p(n)}.$

649 We use an un-informative prior on the probability of infection, i.e. $p(r) \sim \text{Beta}(1,1)$. An equivalent model is used for the risk of infection after vaccination, r_n , with the vaccine 650 651 effectiveness E = 1 - OR, where OR is the odds ratio (of the risk of infection between unvaccinated and vaccinated individuals). Under the assumption of a rare disease $(r \ll 1)$, the 652 odds ratio, risk ratio and hazard ratio converge. 653 For all studies, we used the most temporally disaggregated data available (Table S1). This 654 allows us to better account for changes in incidence and vaccine coverage over the outbreak. 655 We also used data disaggregated by demographic factors, such as age, where available. 656 Groups or timepoints in which no cases were reported in both control and vaccinated 657 populations were excluded from the analysis. We assumed that the baseline risk of infection 658 in unvaccinated individuals could differ for temporally or spatially disaggregated groups 659 from the same study, but we assumed the vaccine effectiveness was constant. That is, for a 660 given study, s, we had pairs of data $(n_{i,v,s}, N_{i,v,s})$, where, $n_{i,v,s}$ is the number of infections and 661 $N_{i,v,s}$ the total individuals of the disaggregation group i, with vaccine v, in study s. We 662 estimate a different baseline risk in unvaccinated individuals (v = 0), $r_{i,0,s}$, for disaggregation 663 group i, and a fixed vaccine effectiveness E_v . The risk of infection after vaccination ($v \neq 0$) 664 665 is then given by, $logit(r_{i,v,s}) = logit(r_{i,0,s}) + log(1 - E_v) + S_s$ 666 1 where S_s is the random effect on the risk reduction from vaccination (on the logit scale) in 667 each study. These random effects are defined by the hierarchical structure $S_s \sim N(0, \sigma)$ 668 (further detail in supplementary methods), where σ is to be estimated. The posterior 669 distribution is defined using the likelihood function, 670 671 $n_{i,v,s} \sim Bin(r_{i,v,s}, N_{i,v,s}).$ 2 and with the priors, 672 673 $r_{i,0,s} \sim \text{Beta}(1,1),$ $R_{\nu} \sim N(0,10)$, 674 $\sigma\sim$ Half-Cauchy(0.25). 675 676 For the case-control studies, the at-risk population is not used. However, vaccine effectiveness can be estimated using the odds ratio comparing the odds of vaccination in the 677 678 infection and control groups⁵⁷. Subsequently we can use the same model (Equation 1 and 2)

to fit the case-control studies (detailed in Supplementary methods).

679

680

Estimating immunogenicity

Our goal here is to estimate the mean vaccinia-binding titer induced by vaccination in each group, as well as the spread (standard deviation) of those titers between individuals (since this is important when relating antibody titers to protection³⁸). That is, we aim to estimate the mean, μ_v , and standard deviation, σ_v , of the distribution of antibody titers induced in a population after vaccination for a given vaccine regimen, v. Since we do not have individual level data from each study, we are limited to using only three pieces of data for each group, from each study, to estimate these quantities. Specifically, the (log) GMT reported after vaccination, $\bar{y}_{s,v,f,E}$, the number of individuals in these groups, $n_{s,v,f,E}$, and the standard deviation of the (log) titers in these groups, $\bar{sd}_{s,v,f,E}$ (derived from the reported confidence intervals, Supplementary Methods) – in each study, s, and for each vaccine group, v (accounting for different assays, e, and vaccine formulations, f). We assume that individuals' (log) vaccinia-binding titers after vaccination are normally distributed, i.e.

695
$$y_{i,s,v,f,E} \sim N(\mu_v + \mu_s + \mu_f + \mu_E, \sigma_v),$$

where the mean and standard deviation of titers after vaccination with vaccine v are μ_v and σ_v (respectively), and assuming this mean is influenced by: (i) random study effects, μ_s (from a hierarchical model structure, where $\mu_S \sim N(0,\sigma_s)$, and σ_s , is also a parameter that is inferred), (ii) a fixed effect, μ_f , to account for potential differences in antibody titers induced by the two different vaccine formulations used for the MVA-BN vaccine (freeze dried and liquid frozen), and (iii) a fixed effect, μ_E , to account for the effect of the different ELISA assays (but the latter was not a significant covariate, and removed from further analysis). We use the above model to estimate the distribution of the participant level vaccinia-binding titers, using the sample mean, $\bar{y}_{s,v,f,E}$, and sample standard deviation, $s\bar{d}_{s,v,f,E}$ from each group/study as 'sufficient statistics' to estimate this distribution (i.e. we require no other information to estimate the participant level distribution of vaccinia-binding titers other than the available sample means and standard deviations - derivation in supplementary material, including likelihood function). We impose the below weakly informative priors on our parameters,

710
$$\mu_d \sim N(0,10)$$
711 $log(\sigma_d) \sim N(0,10)$
712 $\mu_E \sim N(0,10)$
713 $\mu_f \sim N(0,10)$
714 $\sigma_s \sim \text{Half-Cauchy}(0,1).$

When antibody titers were below the limit of detection, this was handled in different ways across the different studies. Some studies had assigned values of "1" to the titers below the detection limit before calculating the GMT, whilst other studies assigned those values as half the limit of detection. For consistency in our analysis, we adjusted the GMTs from the latter studies to reflect the former approach. That is, we used the reported number of seropositive samples (those above the limit of detection) to adjust GMTs from each study such that values below the limit of detection were set to "1".

Predicting vaccine effectiveness over time

- We fit a model of biphasic exponential decay to the vaccinia-binding antibody titers. This
- model has two compartments, long (x_1) and short (x_s) lived antibody titers, which each are
- assumed to decay with rates δ_l and δ_s , respectively. Thus, the total antibody titer at time, t, is
- 728 given by $x(t) = x_l(t) + x_s(t)$, where,

$$x_{s}(t) = x_{0} f e^{-\delta_{s} t},$$

730
$$x_l(t) = x_0(1 - f)e^{-\delta_l t},$$

- and where x_0 is the antibody titer at t = 0 (which is defined as a maximum of 14 days after
- final dose or 28 days after the first dose), and f is the fraction of the initial antibody titer that
- 733 is short-lived. After model comparison (Table S7), we found that the decay rates δ_l and δ_s
- are not significantly different between dosing regimens. However, we assume the initial
- antibody titer (x_0) and the faction short-lived, f, differs for each dosing regimen and is also
- different for historically vaccinated groups. The log (base 10) of the model and data were
- fitted in RStan as described above in the "Estimating immunogenicity" section. We impose
- 738 the weakly informative priors on the decay model parameters.

739
$$\delta_{s}, \delta_{l} \sim N(0,1)$$

740
$$f \sim U(0,1)$$

Fitting the relationship between vaccinia binding antibody titers and protection from

743 **Mpox**

741

742

715

716

717

718

719

720

721

722

723

- To analyse the relation between antibody titers and protection we applied a model we have
- previously used to identify a correlate of protection for COVID-19³⁸. The model assumes that
- 746 there is a logistic relationship between the protection, P, experienced by a group of
- 747 individuals with a given vaccinia-binding antibody titer, x, given by,

$$P(x) = \frac{1}{1 + e^{-k(x - x_{50})}},$$

- where, x_{50} is the 50% protective titer and k describes the steepness of the relation between 749
- the antibody titer and the protection. 750

- 751 We re-parameterize this function with the substitution, $A = -k(2.5 - x_{50})$, to provide better
- numerical stability during model fitting, in cases where the two parameters trade-off, i.e. 752

753
$$P(x) = \frac{1}{1 + e^{-k(x-2.5)-A}}.$$

- For a given vaccinated population, we must consider the observed population distribution of 754
- vaccinia-specific antibody titers (with mean μ and standard deviation σ). The average 755
- protection over the distribution of titers is given by, 756

757
$$VE = \int_{-\infty}^{\infty} P(x)N(x \mid \mu, \sigma) dx$$

- where $N(x|\mu,\sigma)$ denotes the probability density function of the normal distribution. The data 758
- on antibody titers and effectiveness are fitted simultaneously to estimate all model parameters 759
- along with associated credible intervals (Table S5). The priors used and hierarchical structure 760
- (to account for inter-study variability) are also provided in Table S6. 761

763 **Ethics statement** This work was approved under the UNSW Sydney Human Research Ethics Committee 764 765 (approval HC200242). **Conflicts of interest** 766 767 CRM is on the WHO SAGE Working Group on Smallpox and Monkeypox. The authors have 768 no other competing interests to declare. 769 **Funding** This work is supported by an NHMRC program grant GNT1149990 (to MPD), Investigator 770 grants (GNT1173931 to AEG, GNT2016907 to CRM and GNT1173027 to MPD) and an 771 772 NHMRC Centre for Research Excellence BREATHE (GNT2006595). DSK is supported by a 773 University of New South Wales fellowship. The funders had no role in the design and conduct of the study; collection, management, 774 775 analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 776 777 Data and code availability 778 Extracted data and codes for analysis will be made publicly available on GitHub upon 779 publication.